We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Xenical (Orlistat) in Overweight and Obese Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00940628
Recruitment Status : Completed
First Posted : July 16, 2009
Last Update Posted : April 5, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

June 16, 2009
July 16, 2009
April 5, 2016
April 2008
September 2010   (Final data collection date for primary outcome measure)
Change in BMI [ Time Frame: At each clinic visit, every 4 weeks ]
Change in body mass index (BMI) [ Time Frame: At each clinic visit, every 4 weeks ]
Complete list of historical versions of study NCT00940628 on ClinicalTrials.gov Archive Site
Adverse events, laboratory parameters [ Time Frame: At each clinic visit, every 4 weeks ]
Same as current
Not Provided
Not Provided
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive Xenical 120mg po tid. The anticipated time on study treatment is 1 year, and the target sample size is <100 individuals.
Not Provided
Phase 3
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
  • Behavioral: Diet and Exercise
    mildly hypocaloric diet and physical exercise
  • Drug: orlistat [Xenical]
    120mg po tid
  • Experimental: 1
    • Behavioral: Diet and Exercise
    • Drug: orlistat [Xenical]
  • 2
    Intervention: Behavioral: Diet and Exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • adolescent patients, 12-14 years of age
  • overweight or obese

Exclusion Criteria:

  • age <12 or >14 years
  • BMI in normal range
Sexes Eligible for Study: All
12 Years to 14 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Russian Federation
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP